Their multifaceted mechanisms, including anti-inflammatory and diuretic effects, position them as potential therapeutic agents for liver disease beyond glycemic control. While preclinical and clinical evidence highlights the potential benefits of SGLT2 inhibitors in cirrhosis-related complications such as ascites, HCC, and possibly HRS, caution is necessary due to limited data and the risk of adverse effects, such as acute kidney injury and infections. The gene discussed is SLC5A2; the disease is infection.